China High Quality L(+)-Tartaric Acid Factory – 99% Apixaban CAS 503612-47-3 – Baoran

Short Description:

Product Detail

Product Tags

Feedback (2)

We emphasize advancement and introduce new products into the market each year for Cas 14898-67-0, Mesitylene, Perchloroethylene Pce, We promise to try our best to provide you with high quality and efficient services.

China High Quality L(+)-Tartaric Acid Factory – 99% Apixaban CAS 503612-47-3 – Baoran Detail:

Specification

ITEM	STANDARD
Appearance	White to off-white solid
Purity	≥ 99%

Application

On April 26, 2007, Bristol-Myers Squibb and Pfizer announced a joint development of the new oral anticoagulant apixaban owned by Bristol-Myers Squibb as an upgraded alternative to warfarin.
In May 2011, apixaban was the first to be approved for the prevention of venous thrombosis in adult patients undergoing elective hip or knee replacement surgery in 27 EU countries, Iceland and Norway.
On November 20, 2012, the European Commission approved ELIQUIS (apixaban) for the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) with one or more risk factors.
The Canadian Food and Drug Administration, Japan, and the U.S. Food and Drug Administration subsequently approved ELIQUIS (apixaban) for the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) with one or more risk factors.
On April 12, 2013, ELIQUIS (Apixaban), was officially announced on the market in China. Apixaban is a novel oral factor Xa inhibitor for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery. Its launch provides a safe and effective new option for anticoagulation after orthopaedic surgery in clinical practice, and brings good news to Chinese patients undergoing elective hip/knee replacement.
Clinical studies have confirmed that compared with 40 mg subcutaneous injection of enoxaparin once a day, 2.5 mg of ELIQUIS (Apixaban) orally twice a day is more effective in preventing venous thromboembolic events after hip or knee replacement surgery , and does not increase the risk of bleeding.

Packing & Storage

100g/500g/1kg/25kg or as request;
Stored at room temperature and airtight.

Product detail pictures:

Related Product Guide:

Bear "Customer 1st, Good quality first" in mind, we work closely with our prospects and supply them with efficient and professional services for China High Quality L(+)-Tartaric Acid Factory – 99% Apixaban CAS 503612-47-3 – Baoran, The product will supply to all over the world, such as: Italy, Argentina, UK, We maintain long-term efforts and self-criticism, which helps us and improvement constantly. We strive to improve customer efficiency to save costs for customers. We do our best to improve the quality of product. We will not live up to the historic opportunity of the times.

Products and services are very good, our leader is very satisfied with this procurement, it is better than we expected,